As we await the results of the VISION trial of Lu-177-PSMA-617, research continues into improving radiopharmaceuticals. … READ MORE …
Filed under: Drugs in development | Tagged: Ac-225, actinium-225, PSMA, radiopharmaceuticals, safety, side effects, targeted, xerostomia | 3 Comments »
We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, outcome, photodynamic, surveillance, targeted, TOOKAD, vascular, VTP | 3 Comments »
A new review article offers us some greater clarity related to the role of targeted, high-intensity focused ultrasound (HIFU) to treat carefully selected areas of the prostate to eliminate primary or index lesions while leaving the remainder of the prostate intact. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ablation, focused, HIFU, high-intensity, partial, targeted, ultrasound | 2 Comments »
The answer to that question, at present, is that we don’t know — but it’s probably very few indeed compared to all the men who have progressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: genome, informed, oncology, precision, targeted | 1 Comment »
A new article in this week’s New England Journal of Medicine has just reported the full results of the so-called PRECISION trial of MRI-targeted vs. standard biopsy techniques in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, outcome, standard, targeted | 5 Comments »
A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: analysis, genetic, genomic, targeted, testing, therapy | 2 Comments »
There has been no really clear and formal guidance available on how to monitor patients for risk of prostate cancer after a first, negative, standard, 12-core, systematic biopsy. New guidance from the American Urological Association (AUA) and the Society of Abdominal Radiology (SAR) may be helpful in addressing this situation. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, MRI, negative, risk, scan, targeted | 3 Comments »
A significant number of patients have wanted to believe that, with the coming of targeted biopsies based on multiparametric MRI imaging, the need for “random” systematic biopsies (e.g., standard 10- or 12-core biopsies) would go away. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: fusion-guided, MRI, MRI/TRUS, multiparametric, systematic, targeted | 6 Comments »
Although it has no immediate relevance to the treatment of prostate cancer, it is worth noting that the results of the very first, completed and published “basket” type of clinical trial appear in this week’s issue of the New England Journal of Medicine (NEJM). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: basket, expression, gene, outcome, targeted, therapy, trial | 6 Comments »
A new study that is in press on line in the Journal of Urology addresses, very reasonably, the question of whether using targeted biopsy methods based on multiparametric MRI (mpMRI) data is improving our ability to accurately assess patient’s Gleason grades and scores prior to decisions about treatment. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: accuracy, biopsy, Gleason, MRI, multiparamentric, targeted | 7 Comments »
An article just published in the Journal of Urology argues that, ” The gold standard for cancer detection in primary biopsy is [now] a combination of systematic and targeted cores.” . READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, MRI/TRUS fusion, systematic, targeted | 1 Comment »
There is a distinctly “odd” paper in the December 2014 issue of the Journal of Urology on optimization of the use of MRI/TRUS fusion-guided biopsies in men suspected of having prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, cutoff, MRI/TRUS fusion, PSA, targeted | 3 Comments »
The potential role of targeted focal therapy in the management of localized prostate cancer is yet to be well-defined, so a paper just published on line in the Journal of Urology is of value in helping us to set our expectations. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cryotherapy, focal, outcome, targeted, therapy | 5 Comments »
A pair of articles currently scheduled for publication in the December issue of the Journal of Urology has just appeared on line under the title “MRI before prostate biopsy — yes or no?” Unfortunately for our readers, access to this pair of articles is limited to subscribers to the journal (unless you want to pay), and there is no abstract. So we will try to summarize the key points. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, biopsy, Diagnosis, MRI, risk, targeted | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 